By Dean Seal
Vesicor Therapeutics has signed a deal to combine with special purpose acquisition company Black Hawk Acquisition.
The blank-check company said Monday that it has reached a business-combination agreement with Vesicor, a California biotechnology company.
Vesicor was founded in 2008 and focuses on the development of p53-based cancer therapeutics delivered through microvesicles.
The transaction, which has been approved by the boards of both companies, gives Vesicor a pre-money equity value of $70 million.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 28, 2025 18:33 ET (22:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.